David
Fitzgibbon
Partner
David is a partner and Head of the Firm’s Corporate M&A Group and the Corporate Department.
He has extensive experience assisting clients across a range of industries on doing business in and from Ireland, including advising on acquisitions/disposals, capital raisings, corporate migrations, cross-border mergers, joint ventures and reorganisations. He has a long track record in public and private M&A and is well known for his market-leading expertise in take-private transactions.
David has advised on numerous landmark and high-profile transactions in recent years. His practice reflects his considerable experience across the agri-food, manufacturing, financial services and healthcare / life sciences sectors.
David is widely recognised as a senior strategic adviser to boards and executive leadership teams of major Irish and global corporations. He regularly provides counsel on corporate governance, operational issues, complex risk considerations and long-term organisational planning, and is valued for his ability to combine commercial pragmatism with a rigorous understanding of regulatory and market dynamics.”
Experience and Education
David has recently advised:
- Tirlán Co-operative Society Limited on an equity placing of a portion of its shareholding in Glanbia plc (raising gross proceeds of approximately €230m) and the concurrent tender offer to repurchase its outstanding €250m Exchangeable Bond;
- Smurfit Kappa Group plc on its $25.5 billion merger with WestRock Company to form Smurfit Westrock;
- Horizon Therapeutics on all aspects of its acquisition by Amgen for aggregate consideration of $27 billion;
- Zoom Video Communications, Inc on its acquisition of employee communication and engagement platform, Workvivo;
- Novo Nordisk A/S on its acquisition of Neotope Neuroscience Limited for $100 million upfront and up to $1.2 billion in development and sales milestones payments;
- Horizon Therapeutics on its $960 million underwritten public offering of ordinary shares;
- Willis Towers Watson plc on its proposed $80 billion business combination with Aon plc.;
- Tirlán Co-operative Society Limited on all aspects of its acquisition of Glanbia plc’s interest in Glanbia Ireland, a dairy processing and consumer goods joint venture formed between Tirlán Co-operative Society Limited and Glanbia plc.;
- Tirlán Co-operative Society Limited on all aspects of the funding arrangements for its acquisition of Glanbia plc’s 40% interest in Glanbia Ireland. (raising approximately €310m) comprised of a share placing by Tirlán Co-op of approximately 2% of Glanbia plc’s issued share capital together with the issue by Tirlán Co-op of a €250m equity-linked exchangeable bond;
- Horizon Therapeutics on its acquisition of EirGen Pharma’s manufacturing facility in Waterford; and
- Smurfit Kappa Group on its November 2020 €660 million Share Placing.
- Council of Irish Management Institute
- Trinity College Dublin (LLB with German)
- Law Society of Ireland, admitted as a solicitor
